Updates in the Treatment of Metastatic Melanoma

Description: Melanoma is the fifth most frequently diagnosed malignancy in the United States, with 99,780 new melanoma cases estimated for 2022. Melanoma is more common in men compared to women, individuals with fair completion, and people with sun exposure (natural/artificial) over prolonged periods of time.1 Nine percent of newly diagnosed patients have regional lymph node involvement, with a 5-year relative survival of 70.6%. Unfortunately, four percent of newly diagnosed patients have metastatic disease at diagnosis, with a 5-year relative survival of 31.9%.  The clinical approach to treating metastatic melanoma have drastically changed with the advances in immunotherapy and targeted therapy, with improvements in survival rates and quality of life. In this presentation, we will discuss the relevant literature and guideline updates for treatment of newly diagnosed stage IV metastatic melanoma patients and identify which patients may be good candidates for the newly approved medication, relatlimab+nivolumab.

Speaker: Jocelyn Joseph, PharmD, BCOP, MD Anderson

Tebentafusp-tebn for Treatment of Metastatic Uveal Melanoma

Description: The goal of this activity is to review treatment options for uveal melanoma. There will also be discussion of the role of tebentafusp-tebn in the treatment of metastatic uveal melanoma. Lastly, the goal of this lecture is to describe the administration and management of toxicities associated with tebentafusp-tebn.

Speaker: Anna Jan, PharmD, BCOP, MD Anderson